API Holdings, which operates the giant healthcare startup PharmEasy, said on Friday it has reached an agreement to acquire 66.1% stake in Thyrocare, which runs a diagnostic lab chain, for about $613 million in what is the first ever acquisition of a listed firm by an unicorn startup in the world’s second most populated nation.
The transaction is subject to regulatory and other applicable customary approvals. Docon Technologies Pvt Ltd, a 100% subsidiary of API, will be the acquirer and shall make an open offer for an additional 26% stake for over $241 million, the startup said in a statement.
PharmEasy is India’s largest online pharmacy and diagnostics brand. It operates a business-to-business pharma marketplace with over 6,000 consultation clinics with 90,000 partner retailers across the South Asian nation. The five-year-old startup, which has raised about $572 million to date and was last valued at $1.5 billion, counts Prosus, Temasek, Eight Roads Ventures, TPG, B Capital Group, and Bessemer Venture Partners among its investors.
Thyrocare is India’s largest diagnostics solution provider by volume (it performs over 110 million tests in a year). The 26-year-old firm also operates a network of over 3,330 collection centres across in 2,000+ towns in India.
“We are delighted to be partnering Thyrocare. We will provide world class customer experience in diagnostics, rivalling our pharmacy experience by leveraging technology, and building on top of the massive scale & truly pan-India presence of Thyrocare. It is our aim to deliver all outpatient healthcare products & services to every Indian within 24 hours,” said 32-year-old Siddharth Shah, CEO of API Holdings, in a statement.
“I am excited about this relationship, unique of its kind in Indian Healthcare Industry. The unique reach and strength of Thyrocare in Diagnostics blended with young and dynamic team of PharmEasy will bring in better healthcare solutions for common man nationwide,” said 62-year-old Dr A. Velumani, Chairman and MD of Thyrocare, in a statement.
This is a developing story. More to follow…